Publications
Partners
Shutterstock
Leaders of research-based pharmaceutical industries have called for continued dialogue and engagement as governments gather in New York to review efforts for the achievement of the United Nations millennium development goals. They want to chart a new pathway for global development beyond 2015.
With more than 220 global partnerships addressing a wide range of diseases and focusing on prevention, improvements in health system infrastructures, training, pharmaceutical R&D, and medicine and vaccine donations, the industry plays an important role in advancing progress toward the health-related development goals.
A new publication launched by the international federation of pharmaceutical manufacturers & associations shows that transformative partnerships and accountability frameworks between civil society, the private sector and governments can promote more equitable, inclusive and sustainable development.
Meeting unmet needs
The director general of the international federation of pharmaceutical manufacturers & associations, Eduardo Pisani, says "there is need to pool efforts as never before.
"This call for action resonates strongly with the research-based pharmaceutical industry – where expanding access to healthcare and meeting unmet medical needs are at the very core of our daily operations."
Pisani said emerging issues such as diabetes, cancer, respiratory and cardiovascular diseases would increasingly challenge health systems worldwide in the next 15 years.
Development goals
Nearly 80% of deaths due to these 'non-communicable' diseases occur in low- and middle-income countries and will inevitably increase pressure to find cost-effective interventions to prevent or treat diseases.
"To maximize the impact of private sector action on global health goals, we need proactive, cross-sector engagement in framing the next set of development goals," said Pisani.
"The original development goals were conceived without a clear map as to how the private sector could contribute, but pharmaceutical companies came to the fore anyway. They recognised the need that existed for their unique contributions."
Photo: Pharmaceutical industry from Shutterstock
With more than 220 global partnerships addressing a wide range of diseases and focusing on prevention, improvements in health system infrastructures, training, pharmaceutical R&D, and medicine and vaccine donations, the industry plays an important role in advancing progress toward the health-related development goals.
A new publication launched by the international federation of pharmaceutical manufacturers & associations shows that transformative partnerships and accountability frameworks between civil society, the private sector and governments can promote more equitable, inclusive and sustainable development.
Meeting unmet needs
The director general of the international federation of pharmaceutical manufacturers & associations, Eduardo Pisani, says "there is need to pool efforts as never before.
"This call for action resonates strongly with the research-based pharmaceutical industry – where expanding access to healthcare and meeting unmet medical needs are at the very core of our daily operations."
Pisani said emerging issues such as diabetes, cancer, respiratory and cardiovascular diseases would increasingly challenge health systems worldwide in the next 15 years.
Development goals
Nearly 80% of deaths due to these 'non-communicable' diseases occur in low- and middle-income countries and will inevitably increase pressure to find cost-effective interventions to prevent or treat diseases.
"To maximize the impact of private sector action on global health goals, we need proactive, cross-sector engagement in framing the next set of development goals," said Pisani.
"The original development goals were conceived without a clear map as to how the private sector could contribute, but pharmaceutical companies came to the fore anyway. They recognised the need that existed for their unique contributions."
Photo: Pharmaceutical industry from Shutterstock
